A substantial reduction in gBRCA testing <*> was registered ,
These evidences further emphasize the new era of gBRCA testing in the management of cancer patients
A substantial reduction in gBRCA testing ( about 60 % ) compared to the first 2 months of the current year was registered , but the requests have not been reset .
These evidences further emphasize the new era of gBRCA testing in the management of cancer patients and confirms definitively the integration of gBRCA testing / Next Generation Sequencing ( NGS ) into clinical oncology .